Solventum (NYSE:SOLV) Earns "Hold (C-)" Rating from Weiss Ratings

Key Points

• Solventum (NYSE:SOLV) has been assigned a "Hold (C-)" rating by Weiss Ratings, indicating a neutral outlook on the stock's performance.
• Several analysts have diverse opinions on the stock, with Morgan Stanley upgrading it to "overweight" and a price target increase to $103.00, while UBS Group set a price target at $77.00.
• For the most recent quarter, Solventum reported $1.69 earnings per share, exceeding analysts' expectations and showing a revenue increase of 3.8% year-over-year.

Solventum (NYSE:SOLV - Get Free Report)'s stock had its "hold (c-)" rating reissued by Weiss Ratings in a report issued on Wednesday,Weiss Ratings reports.

Several other equities research analysts have also recently issued reports on the company. UBS Group assumed coverage on Solventum in a research note on Wednesday, October 1st. They issued a "neutral" rating and a $77.00 price target for the company. Jefferies Financial Group assumed coverage on Solventum in a research note on Thursday, September 11th. They issued a "hold" rating and a $80.00 price target for the company. Morgan Stanley upgraded Solventum from an "equal weight" rating to an "overweight" rating and upped their target price for the stock from $80.00 to $103.00 in a research note on Tuesday, July 15th. Wall Street Zen cut Solventum from a "strong-buy" rating to a "buy" rating in a research note on Tuesday, September 9th. Finally, Zacks Research upgraded Solventum from a "hold" rating to a "strong-buy" rating in a research note on Monday, September 15th. One analyst has rated the stock with a Strong Buy rating, three have assigned a Buy rating, seven have assigned a Hold rating and one has assigned a Sell rating to the company's stock. According to MarketBeat.com, the stock currently has a consensus rating of "Hold" and an average price target of $84.89.

Solventum Stock Performance

NYSE SOLV traded up $0.23 during trading on Wednesday, reaching $72.39. 827,221 shares of the company's stock were exchanged, compared to its average volume of 1,193,227. The business has a 50 day moving average price of $72.77 and a 200-day moving average price of $72.16. The stock has a market capitalization of $12.55 billion, a P/E ratio of 33.51, a PEG ratio of 2.94 and a beta of 0.50. The company has a debt-to-equity ratio of 2.14, a current ratio of 1.22 and a quick ratio of 0.86. Solventum has a fifty-two week low of $60.70 and a fifty-two week high of $85.92.

Solventum (NYSE:SOLV - Get Free Report) last announced its quarterly earnings results on Thursday, August 7th. The company reported $1.69 earnings per share for the quarter, topping analysts' consensus estimates of $1.45 by $0.24. Solventum had a return on equity of 29.93% and a net margin of 4.52%.The firm had revenue of $2.16 billion for the quarter, compared to the consensus estimate of $2.12 billion. During the same quarter in the previous year, the business earned $1.56 earnings per share. The business's revenue was up 3.8% compared to the same quarter last year. Solventum has set its FY 2025 guidance at 5.800-5.950 EPS. Sell-side analysts forecast that Solventum will post 6.58 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Several hedge funds have recently made changes to their positions in the business. Independent Franchise Partners LLP grew its stake in shares of Solventum by 74.2% in the 2nd quarter. Independent Franchise Partners LLP now owns 10,141,066 shares of the company's stock valued at $769,098,000 after buying an additional 4,320,342 shares during the period. Norges Bank acquired a new stake in shares of Solventum in the 2nd quarter valued at about $140,495,000. Boston Partners grew its stake in shares of Solventum by 101.3% in the 1st quarter. Boston Partners now owns 3,361,973 shares of the company's stock valued at $255,554,000 after buying an additional 1,691,565 shares during the period. Assenagon Asset Management S.A. grew its stake in shares of Solventum by 738.3% in the 1st quarter. Assenagon Asset Management S.A. now owns 566,623 shares of the company's stock valued at $43,086,000 after buying an additional 499,031 shares during the period. Finally, Nuveen LLC acquired a new stake in shares of Solventum in the 1st quarter valued at about $35,375,000.

About Solventum

Solventum Corporation, a healthcare company, engages in the developing, manufacturing, and commercializing a portfolio of solutions to address critical customer and patient needs. It operates through four segments: Medsurg, Dental Solutions, Health Information Systems, and Purification and Filtration.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.